| Bioactivity | Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2). Giripladib can be used for osteoarthritis and breast cancer research[1][2]. |
| Name | Giripladib |
| CAS | 865200-20-0 |
| Formula | C41H36ClF3N2O4S |
| Molar Mass | 745.25 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kokotos G, et al. Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. J Med Chem. 2014 Sep 25;57(18):7523-35. [2]. Liu S, et al. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. J Hematol Oncol. 2021 Oct 29;14(1):178. |
Giripladib
CAS: 865200-20-0 F: C41H36ClF3N2O4S W: 745.25
Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2). Giripladib can be used for osteo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.